Patents Assigned to HEFEI LIFEON PHARMACEUTICAL CO. LTD.
-
Patent number: 11970529Abstract: The present invention relates to an epitope on fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domain as well as in targeted cancer therapy.Type: GrantFiled: November 5, 2021Date of Patent: April 30, 2024Assignee: Hefei Lifeon Pharmaceutical Co., Ltd.Inventors: Mei Zhang, Junqiu Ji, Meihua Gao, Jun Chen
-
Patent number: 11878963Abstract: The present disclosure provides a semi-synthetic method of dihydroquercetin, belonging to the field of synthesis of organic drugs. The semi-synthetic method includes the following steps: adding quercetin dihydrate to solvent water adjusted to be alkaline with an alkalizing reagent, heating and stirring to dissolve the mixture, and then adding thiourea dioxide under the protection of an inert gas to perform a reduction reaction, to obtain an endpoint reduction reaction solution; diluting the endpoint reduction reaction solution with water and cooling the resultant, and then acidizing, aging, and filtering the resultant to obtain a filtrate and a filter cake; extracting, washing, drying, concentrating, and repeatedly crystallizing the filtrate to obtain dihydroquercetin; and recycling the filter cake after being washed.Type: GrantFiled: May 7, 2022Date of Patent: January 23, 2024Assignee: HEFEI LIFEON PHARMACEUTICAL CO., LTD.Inventors: Junqiu Ji, Xiaochang Li, Qiao Li, Jun Chen, Bing Li, Ruru Liu, Xiaohong Zhao
-
Patent number: 11753389Abstract: The present disclosure provides a preparation method of dihydroquercetin, belonging to the field of synthesis of drugs. The method includes steps of: adjusting reaction solvent water to be alkaline with an alkalizing reagent, to obtain an alkaline aqueous solution; dissolving quercetin dihydrate in the alkaline aqueous solution, and adding a sulfite binary combined reducing agent to carry out reduction reaction, to obtain an endpoint reduction reaction solution; diluting the endpoint reduction reaction solution with water, and then acidizing, aging, and filtering the resultant to obtain a filtrate and a filter cake; subjecting the filtrate to extraction, washing, drying, and vacuum concentration to obtain a concentrated crude product; and repeatedly crystallizing the concentrated crude product to obtain dihydroquercetin. The preparation method of the present disclosure has readily available raw materials, a simple process, and low production costs, and is particularly suitable for industrial production.Type: GrantFiled: May 7, 2022Date of Patent: September 12, 2023Assignee: HEFEI LIFEON PHARMACEUTICAL CO., LTD.Inventors: Junqiu Ji, Xiaochang Li, Bing Li, Qiao Li, Qing Miao, Limei Liu, Jinping Liu
-
Publication number: 20230192640Abstract: The present disclosure provides a semi-synthetic method of dihydroquercetin, belonging to the field of synthesis of organic drugs. The semi-synthetic method includes the following steps: adding quercetin dihydrate to solvent water adjusted to be alkaline with an alkalizing reagent, heating and stirring to dissolve the mixture, and then adding thiourea dioxide under the protection of an inert gas to perform a reduction reaction, to obtain an endpoint reduction reaction solution; diluting the endpoint reduction reaction solution with water and cooling the resultant, and then acidizing, aging, and filtering the resultant to obtain a filtrate and a filter cake; extracting, washing, drying, concentrating, and repeatedly crystallizing the filtrate to obtain dihydroquercetin; and recycling the filter cake after being washed.Type: ApplicationFiled: May 7, 2022Publication date: June 22, 2023Applicant: HEFEI LIFEON PHARMACEUTICAL CO., LTD.Inventors: Junqiu Ji, Xiaochang Li, Qiao Li, Jun Chen, Bing Li, Ruru Liu, Xiaohong Zhao
-
Publication number: 20230192639Abstract: The present disclosure provides a preparation method of dihydroquercetin, belonging to the field of synthesis of drugs. The method includes steps of: adjusting reaction solvent water to be alkaline with an alkalizing reagent, to obtain an alkaline aqueous solution; dissolving quercetin dihydrate in the alkaline aqueous solution, and adding a sulfite binary combined reducing agent to carry out reduction reaction, to obtain an endpoint reduction reaction solution; diluting the endpoint reduction reaction solution with water, and then acidizing, aging, and filtering the resultant to obtain a filtrate and a filter cake; subjecting the filtrate to extraction, washing, drying, and vacuum concentration to obtain a concentrated crude product; and repeatedly crystallizing the concentrated crude product to obtain dihydroquercetin. The preparation method of the present disclosure has readily available raw materials, a simple process, and low production costs, and is particularly suitable for industrial production.Type: ApplicationFiled: May 7, 2022Publication date: June 22, 2023Applicant: HEFEI LIFEON PHARMACEUTICAL CO., LTD.Inventors: Junqiu Ji, Xiaochang Li, Bing Li, Qiao Li, Qing Miao, Limei Liu, Jinping Liu
-
Publication number: 20220089709Abstract: The present invention relates to an epitope on fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domain as well as in targeted cancer therapy.Type: ApplicationFiled: November 5, 2021Publication date: March 24, 2022Applicant: HEFEI LIFEON PHARMACEUTICAL CO., LTD.Inventors: Mei Zhang, Junqiu Ji, Meihua Gao, Jun Chen
-
Patent number: 11192943Abstract: The present invention relates to an epitope on fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domain as well as in targeted cancer therapy.Type: GrantFiled: September 29, 2018Date of Patent: December 7, 2021Assignee: HEFEI LIFEON PHARMACEUTICAL CO., LTD.Inventors: Mei Zhang, Junqiu Ji, Meihua Gao, Jun Chen
-
Publication number: 20200283511Abstract: The present invention relates to an epitope on fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domain as well as in targeted cancer therapy.Type: ApplicationFiled: September 29, 2018Publication date: September 10, 2020Applicant: HEFEI LIFEON PHARMACEUTICAL CO., LTD.Inventors: Mei Zhang, Junqiu Ji, Meihua Gao, Jun Chen
-
Patent number: 10611830Abstract: The present invention provides an antibody or antibody fragment for specifically recognizing and binding to an ED-B domain of fibronectin. The antibody or antibody fragment can be widely used for in vitro detection and in vivo location of the ED-B protein domain, as well as targeted therapy of tumors.Type: GrantFiled: May 28, 2014Date of Patent: April 7, 2020Assignee: HEFEI LIFEON PHARMACEUTICAL CO. LTD.Inventors: Junqiu Ji, Mei Zhang, Meihua Gao, Jun Chen
-
Publication number: 20180340936Abstract: Disclosed are a use of an ED-B protein as a tissue hyperplasia (such as tumor) marker, a method for detecting the ED-B protein, and a diagnostic kit comprising the ED-B protein. The kit of the present invention comprises a genetically-engineered antibody against the tumor marker ED-B.Type: ApplicationFiled: November 16, 2015Publication date: November 29, 2018Applicant: HEFEI LIFEON PHARMACEUTICAL CO. LTD.Inventors: Junqiu Ji, Mei Zhang, Meihua Gao, Jun Chen